본문으로 건너뛰기
← 뒤로

Assessing the Detection Power of Genome-Wide Copy Number Variation Profiles in Prostate Cancer Using Simulated Shallow Whole-Genome Sequencing Data.

1/5 보강
JCO clinical cancer informatics 📖 저널 OA 43.9% 2024: 1/3 OA 2025: 9/19 OA 2026: 15/35 OA 2024~2026 2026 Vol.10() p. e2500240 OA
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
155 patients with mCRPC were mixed in silico to generate a set of 3,360 mixtures with varying TCs (original, 20%, 10%, 5%, 3%) and sequencing depths (original, 5×, 2×, 1×, 0.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] In this study, through in silico simulations of WGS data, we demonstrate that the genomic scars of two druggable genomic profiles, HRD and TD, can be reliably detected in mCRPC with 1× average sequencing depth and ≥20% TC. Further research is required to correlate these markers with outcome of specific treatments using sWGS.

Pamidimarri Naga S, Slootbeek PHJ, Tolmeijer SH, Gillissen C, Ligtenberg MJL, Mehra N

📝 환자 설명용 한 줄

[PURPOSE] Shallow whole-genome sequencing (sWGS) is a cost-effective approach for detecting genome wide copy number profiles in tumor samples.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Pamidimarri Naga S, Slootbeek PHJ, et al. (2026). Assessing the Detection Power of Genome-Wide Copy Number Variation Profiles in Prostate Cancer Using Simulated Shallow Whole-Genome Sequencing Data.. JCO clinical cancer informatics, 10, e2500240. https://doi.org/10.1200/CCI-25-00240
MLA Pamidimarri Naga S, et al.. "Assessing the Detection Power of Genome-Wide Copy Number Variation Profiles in Prostate Cancer Using Simulated Shallow Whole-Genome Sequencing Data.." JCO clinical cancer informatics, vol. 10, 2026, pp. e2500240.
PMID 41576301 ↗

Abstract

[PURPOSE] Shallow whole-genome sequencing (sWGS) is a cost-effective approach for detecting genome wide copy number profiles in tumor samples. In metastatic castration-resistant prostate cancer (mCRPC), recognizing homologous recombination deficiency (HRD) and tandem duplication (TD) genomic profiles may contribute to improved treatment choices such as poly (ADP-ribose) polymerase inhibitors. This study aims to determine the minimum sequencing depth and tumor content (TC) required to accurately identify these clinically significant genomic profiles using sWGS.

[MATERIALS AND METHODS] Whole-genome sequencing (WGS) data from 168 tumor and matched normal biopsies from 155 patients with mCRPC were mixed in silico to generate a set of 3,360 mixtures with varying TCs (original, 20%, 10%, 5%, 3%) and sequencing depths (original, 5×, 2×, 1×, 0.1×). Copy number variations (CNVs) were analyzed using ichorCNA and WisecondorX at different window sizes.

[RESULTS] An average sequencing depth of 1× at 20% TC was found to be sufficient to detect CNVs with high sensitivity (>0.85) and high specificity (>0.95). For HRD and TD profile detection, ichorCNA at a 50 Kb window size was optimal and a reliable detection of HRD profiles was achieved with a very strong correlation of R = 0.88 ( < 2.2e-16). Detection of TD profiles also remained accurate at these parameters with a strong correlation of R = 0.72 ( < 2.2e-16), although the median length of duplication events increased at lower depths. TC estimation by ichorCNA strongly correlated with full-depth WGS of diploid genomes.

[CONCLUSION] In this study, through in silico simulations of WGS data, we demonstrate that the genomic scars of two druggable genomic profiles, HRD and TD, can be reliably detected in mCRPC with 1× average sequencing depth and ≥20% TC. Further research is required to correlate these markers with outcome of specific treatments using sWGS.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기